Age-related Macular Degeneration // Barbara Blodi // Clinical Trials // Genetics // Ongoing // Dec 01 2020
Biomarker Identification for anti-VEGF Resistance in Exudative AMD
Principal Investigator: Barbara Blodi, MD
Study Coordinator: Bonnie Verges
To identify whether genetic variation or polymorphism in genes that impact angiogenesis can be identified as biomarkers for responsiveness to anti-VEGF therapy in patients with neovascular age-related macular degeneration.
One study visit involving collection of a blood sample for genetic/DNA analysis.
Male or female patients ˃ 50 years of age with diagnosis of age-related macular degeneration in both eyes
Patients with exudative age-related macular degeneration in at least one eye undergoing regular treatment with one or more anti-VEGF agents in the past year. Regular treatment would be 4 or more injections per year.
Presence of atrophy or fibrosis under the center of the macula
Contact Bonnie Verges with questions, 608-265-5292